Francisco Pestana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francisco Pestana has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- T. Grant Belgard
The Bioinformatics CRO, Niceville, USA
3 shared publications - Araks Martirosyan
Discovery Biology, MUNA Therapeutics, Heverlee Belgium
2 shared publications - Matthew Guy Holt
Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal
2 shared publications - Nachiket Dilip Kashikar
OMAPiX GmbH, Langenfeld, Germany
2 shared publications - A. Apresyan
Armenian Bioinformatics Institute, Yerevan, Armenia
1 shared publication A. Bogdoll
Resolve BioSciences GmbH, Monheim am Rhein, Germany
1 shared publication
Latest Publications
- Open Access
A systematic cross-modal approach identifies astrocytic VCAM1 as a regulator of hippocampal synapse development
Astrocyte-mediated cell-cell interactions at synapses are essential for circuit formation, yet the molecular mechanisms underlying astrocyte-mediated regulation of hippocampal synapse development remain incompletely characterized. Here, we take a systematic cross-modal approach to identify novel astrocytic cell surface proteins (CSPs) at the tripartite synapse. By using single-cell spatial transcriptomics (scST) targeting CSPs identified in a previous hippocampal synaptic dataset, we find 10 potential candidate astrocytic CSPs. Subsequent systematic protein-level profiling using multiple antibody-based assays establishes GPR37L1, HepaCAM, and VCAM1 as astrocytic peri-synaptic CSPs. To gain insight into the molecular context in which these proteins operate at synapses, we map their synaptic interaction partners using affinity purification-mass spectrometry (AP-MS), revealing distinct hippocampal synaptic interactomes for GPR37L1 and VCAM1. We then develop a custom multi-metric image-based synapse analysis pipeline to assess the roles of GPR37L1 and VCAM1 in synaptic development, using CRISPR/Cas9-mediated gene knockout (KO) in the mouse hippocampus. While loss of GPR37L1 does not substantially affect excitatory and inhibitory synapses, VCAM1 loss impairs excitatory hippocampal synapse development. Conversely, addition of recombinant VCAM1 to cultured hippocampal neurons increases the density of excitatory synapses. Together, these results identify astrocytic VCAM1 as a regulator of hippocampal synapse development.
Open AccessA systematic cross-modal approach identifies astrocytic VCAM1 as a regulator of hippocampal synapse development
Astrocyte-mediated cell-cell interactions at synapses are essential for circuit formation, yet the molecular mechanisms underlying astrocyte-mediated regulation of hippocampal synapse development remain incompletely characterized. Here, we take a systematic cross-modal approach to identify novel astrocytic cell surface proteins (CSPs) at the tripartite synapse. By using single-cell spatial transcriptomics (scST) targeting CSPs identified in a previous hippocampal synaptic dataset, we find 10 potential candidate astrocytic CSPs. Subsequent systematic protein-level profiling using multiple antibody-based assays establishes GPR37L1, HepaCAM, and VCAM1 as astrocytic peri-synaptic CSPs. To gain insight into the molecular context in which these proteins operate at synapses, we map their synaptic interaction partners using affinity purification-mass spectrometry (AP-MS), revealing distinct hippocampal synaptic interactomes for GPR37L1 and VCAM1. We then develop a custom multi-metric image-based synapse analysis pipeline to assess the roles of GPR37L1 and VCAM1 in synaptic development, using CRISPR/Cas9-mediated gene knockout (KO) in the mouse hippocampus. While loss of GPR37L1 does not substantially affect excitatory and inhibitory synapses, VCAM1 loss impairs excitatory hippocampal synapse development. Conversely, addition of recombinant VCAM1 to cultured hippocampal neurons increases the density of excitatory synapses. Together, these results identify astrocytic VCAM1 as a regulator of hippocampal synapse development.
- Top Cited PapersOpen Access
- 18 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Traumatic brain injury promotes neurogenesis at the cost of astrogliogenesis in the adult hippocampus of male mice
Traumatic brain injury (TBI) can result in long-lasting changes in hippocampal function. The changes induced by TBI on the hippocampus contribute to cognitive deficits. The adult hippocampus harbors neural stem cells (NSCs) that generate neurons (neurogenesis), and astrocytes (astrogliogenesis). While deregulation of hippocampal NSCs and neurogenesis have been observed after TBI, it is not known how TBI may affect hippocampal astrogliogenesis. Using a controlled cortical impact model of TBI in male mice, single cell RNA sequencing and spatial transcriptomics, we assessed how TBI affected hippocampal NSCs and the neuronal and astroglial lineages derived from them. We observe an increase in NSC-derived neuronal cells and a concomitant decrease in NSC-derived astrocytic cells, together with changes in gene expression and cell dysplasia within the dentate gyrus. Here, we show that TBI modifies NSC fate to promote neurogenesis at the cost of astrogliogenesis and identify specific cell populations as possible targets to counteract TBI-induced cellular changes in the adult hippocampus.
- 18 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Top Cited PapersOpen AccessTraumatic brain injury promotes neurogenesis at the cost of astrogliogenesis in the adult hippocampus of male mice
Traumatic brain injury (TBI) can result in long-lasting changes in hippocampal function. The changes induced by TBI on the hippocampus contribute to cognitive deficits. The adult hippocampus harbors neural stem cells (NSCs) that generate neurons (neurogenesis), and astrocytes (astrogliogenesis). While deregulation of hippocampal NSCs and neurogenesis have been observed after TBI, it is not known how TBI may affect hippocampal astrogliogenesis. Using a controlled cortical impact model of TBI in male mice, single cell RNA sequencing and spatial transcriptomics, we assessed how TBI affected hippocampal NSCs and the neuronal and astroglial lineages derived from them. We observe an increase in NSC-derived neuronal cells and a concomitant decrease in NSC-derived astrocytic cells, together with changes in gene expression and cell dysplasia within the dentate gyrus. Here, we show that TBI modifies NSC fate to promote neurogenesis at the cost of astrogliogenesis and identify specific cell populations as possible targets to counteract TBI-induced cellular changes in the adult hippocampus.
- Open Access
Unravelling cell type specific response to Parkinson’s Disease at single cell resolution
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder and is generally characterized by impaired motor functions. It currently affects 6.3 million people aged 60 years and more, worldwide. The pathological hallmarks of PD are Lewy bodies (abnormal aggregation of α-synuclein inside cells), which are observed primarily in the substantia nigra (SN) region of the midbrain. It is yet not known how different cell types in SN respond during PD and what are the molecular mechanisms underlying neurodegeneration. To address this question, we generated a large-scale single cell transcriptomics dataset from human post-mortem SN tissue of 29 donors including 15 sporadic cases and 14 controls. We obtained data for a total of ∼80K nuclei, representing major cell types of the brain (including neurons, astrocytes, microglia and oligodendrocytes). Pathway and differential gene expression analysis revealed multicellular character of PD pathology involving major cellular response from neuronal and glial cells.
Open AccessUnravelling cell type specific response to Parkinson’s Disease at single cell resolution
Parkinson’s Disease (PD) is the second most common neurodegenerative disorder and is generally characterized by impaired motor functions. It currently affects 6.3 million people aged 60 years and more, worldwide. The pathological hallmarks of PD are Lewy bodies (abnormal aggregation of α-synuclein inside cells), which are observed primarily in the substantia nigra (SN) region of the midbrain. It is yet not known how different cell types in SN respond during PD and what are the molecular mechanisms underlying neurodegeneration. To address this question, we generated a large-scale single cell transcriptomics dataset from human post-mortem SN tissue of 29 donors including 15 sporadic cases and 14 controls. We obtained data for a total of ∼80K nuclei, representing major cell types of the brain (including neurons, astrocytes, microglia and oligodendrocytes). Pathway and differential gene expression analysis revealed multicellular character of PD pathology involving major cellular response from neuronal and glial cells.
- Open Access
- 10 September 2021
- Published by Springer Nature in Neuroinformatics
- Vol. 20 (3) , 825
Correction to: High‑throughput Analysis of Synaptic Activity in Electrically Stimulated Neuronal Cultures
- 10 September 2021
- Published by Springer Nature in Neuroinformatics
- Vol. 20 (3) , 825
Open AccessCorrection to: High‑throughput Analysis of Synaptic Activity in Electrically Stimulated Neuronal Cultures
- Open Access
- 13 March 2020
- Published by MDPI AG in Brain Sciences
- Vol. 10 (3) , 168
No Longer Underappreciated: The Emerging Concept of Astrocyte Heterogeneity in Neuroscience
Astrocytes are ubiquitous in the central nervous system (CNS). These cells possess thousands of individual processes, which extend out into the neuropil, interacting with neurons, other glia and blood vessels. Paralleling the wide diversity of their interactions, astrocytes have been reported to play key roles in supporting CNS structure, metabolism, blood-brain-barrier formation and control of vascular blood flow, axon guidance, synapse formation and modulation of synaptic transmission. Traditionally, astrocytes have been studied as a homogenous group of cells. However, recent studies have uncovered a surprising degree of heterogeneity in their development and function, in both the healthy and diseased brain. A better understanding of astrocyte heterogeneity is urgently needed to understand normal brain function, as well as the role of astrocytes in response to injury and disease.
- 13 March 2020
- Published by MDPI AG in Brain Sciences
- Vol. 10 (3) , 168
Open AccessNo Longer Underappreciated: The Emerging Concept of Astrocyte Heterogeneity in Neuroscience
Astrocytes are ubiquitous in the central nervous system (CNS). These cells possess thousands of individual processes, which extend out into the neuropil, interacting with neurons, other glia and blood vessels. Paralleling the wide diversity of their interactions, astrocytes have been reported to play key roles in supporting CNS structure, metabolism, blood-brain-barrier formation and control of vascular blood flow, axon guidance, synapse formation and modulation of synaptic transmission. Traditionally, astrocytes have been studied as a homogenous group of cells. However, recent studies have uncovered a surprising degree of heterogeneity in their development and function, in both the healthy and diseased brain. A better understanding of astrocyte heterogeneity is urgently needed to understand normal brain function, as well as the role of astrocytes in response to injury and disease.
- Open Access
- 20 July 2018
- Published by Wiley in Alzheimer's & Dementia
- Vol. 14 (10) , 1261-1280
Generation of a human induced pluripotent stem cell–based model for tauopathies combining three microtubule‐associated protein TAU mutations which displays several phenotypes linked to neurodegeneration
Introduction: Tauopathies are neurodegenerative diseases characterized by TAU protein–related pathology, including frontotemporal dementia and Alzheimer's disease among others. Mutant TAU animal models are available, but none of them faithfully recapitulates human pathology and are not suitable for drug screening.Methods: To create a new in vitro tauopathy model, we generated a footprint‐free triple MAPT‐mutant human induced pluripotent stem cell line (N279K, P301L, and E10+16 mutations) using clustered regularly interspaced short palindromic repeats‐FokI and piggyBac transposase technology.Results: Mutant neurons expressed pathogenic 4R and phosphorylated TAU, endogenously triggered TAU aggregation, and had increased electrophysiological activity. TAU‐mutant cells presented deficiencies in neurite outgrowth, aberrant sequence of differentiation to cortical neurons, and a significant activation of stress response pathways. RNA sequencing confirmed stress activation, demonstrated a shift toward GABAergic identity, and an upregulation of neurodegenerative pathways.Discussion: In summary, we generated a novel in vitro human induced pluripotent stem cell TAU‐mutant model displaying neurodegenerative disease phenotypes that could be used for disease modeling and drug screening.
- 20 July 2018
- Published by Wiley in Alzheimer's & Dementia
- Vol. 14 (10) , 1261-1280
Open AccessGeneration of a human induced pluripotent stem cell–based model for tauopathies combining three microtubule‐associated protein TAU mutations which displays several phenotypes linked to neurodegeneration
Introduction: Tauopathies are neurodegenerative diseases characterized by TAU protein–related pathology, including frontotemporal dementia and Alzheimer's disease among others. Mutant TAU animal models are available, but none of them faithfully recapitulates human pathology and are not suitable for drug screening.Methods: To create a new in vitro tauopathy model, we generated a footprint‐free triple MAPT‐mutant human induced pluripotent stem cell line (N279K, P301L, and E10+16 mutations) using clustered regularly interspaced short palindromic repeats‐FokI and piggyBac transposase technology.Results: Mutant neurons expressed pathogenic 4R and phosphorylated TAU, endogenously triggered TAU aggregation, and had increased electrophysiological activity. TAU‐mutant cells presented deficiencies in neurite outgrowth, aberrant sequence of differentiation to cortical neurons, and a significant activation of stress response pathways. RNA sequencing confirmed stress activation, demonstrated a shift toward GABAergic identity, and an upregulation of neurodegenerative pathways.Discussion: In summary, we generated a novel in vitro human induced pluripotent stem cell TAU‐mutant model displaying neurodegenerative disease phenotypes that could be used for disease modeling and drug screening.